@inproceedings{inproceedings, title = {{CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL}}, url = {{}}, year = {{2023}}, month = {{1}}, author = {{Jones C and Sachdeva A and Murphy L and Murray M and Brown L and McCloskey E and Brown J and Attard G and Parmar M and James N and Sydes M et al}}, volume = {{209}}, journal = {{JOURNAL OF UROLOGY}}, pages = {{E129-E129}}, note = {{Accessed on 2025/05/21}}}